

( (S (NP-SBJ-3 (NP The amount)
               (PP of
                   (NP (NP blood)
                       (SBAR (WHNP-1 0)
                             (S (NP-SBJ surgical patients)
                                (VP can
                                    (VP donate
                                        and
                                        store
					(NP *T*-1)
                                        (PP-TMP before
						(NP surgery)))))))))
     (VP can
         (VP be
             (VP increased
                 (NP *-3)
                 (PP by
                     (NP-LGS (NP the new (ADJP genetically engineered) drug)
			     ,
			     (NP EPO))))))
     .))
( (S (NP-SBJ (NP EPO)
             , or
             (NP erythropoietin)
             ,)
     (VP is
         (NP-PRD (NP a protein)
		 (SBAR (WHNP-1 0)
		       (S (NP-SBJ-2 the human body)
			  (VP makes
			      (NP *T*-1)
			      (S-PRP (NP-SBJ *-2)
				     (VP to
					 (VP stimulate
					     (NP (NP the growth)
						 (PP of
						     (NP red blood cells)))))))))))
     .))
( (S (NP-SBJ-1 (NP A (ADJP genetically engineered) version)
	       (PP of
		   (NP the human protein))
               (VP developed
                   (NP *)
                   (PP by
                       (NP-LGS (NP Amgen Corp.)
                               (PP of
                                   (NP (NP Thousand Oaks)
                                       ,
                                       (NP Calif.)
                                       ,))))))
     (ADVP-TMP recently)
     (VP has
         (VP been
             (VP marketed
                 (NP *-1)
                 (PP by
                     (NP-LGS (NP the Ortho Pharmaceuticals division)
			     (PP of
				 (NP Johnson & Johnson)))))))
     .))
( (S (NP-SBJ-1 (NP A competing version)
               (PP of
                   (NP EPO)))
     (VP is
         (VP being
             (VP developed
                 (NP *-1)
                 (PP by
                     (NP-LGS (NP Genetics Institute Inc.)
			     (PP-LOC in
				     (NP (NP Cambridge)
					 ,
					 (NP Mass))))))))
     .))
( (S (NP-SBJ-1 The drug)
     (VP is
         (VP being
             (VP used
                 (NP *-1)
                 (ADVP primarily)
                 (S-CLR (NP-SBJ *)
			(VP to
			    (VP treat
				(NP anemias)))))))
     .))
( (S (NP-SBJ (NP A new experiment)
             ,
             (VP reported
                 (NP *)
                 (PP-LOC in
			 (NP (NP (NP this week 's)
				 New England Journal) 
			     (PP of
				 (NP Medicine)))))
             ,)
     (VP involved
         (S (NP-SBJ *)
	    (VP giving
		(NP (NP injections)
		    (PP of
			(NP (NP Amgen 's)
			    EPO)))
		(PP-DTV to
			(NP (NP 23 patients)
			    (SBAR (WHNP-1 who)
				  (S (NP-SBJ-2 *T*-1)
				     (VP wanted
					 (S (NP-SBJ *-2)
					    (VP to
						(VP store
						    (NP (NP units)
							(PP of
							    (NP their own blood))))))))))))))
     .))
( (S (NP-SBJ-1 The patients)
     (VP began
         (S (NP-SBJ *-1)
            (VP receiving
                (NP EPO injections)
		(PP-TMP (NP-ADV (QP about a) month) 
			before
			(NP their scheduled surgery)))))
     .))
( (S (NP-SBJ-1 They)
     (ADVP-TMP then)
     (VP began
         (S (NP-SBJ-2 *-1)
            (VP donating
                (NP blood)
                (NP-TMP twice a week)
                ,
                (S-ADV (NP-SBJ *-2)
		       (VP receiving
			   (NP an EPO injection)
			   (NP-TMP each time))))))
     .))
( (S (SBAR-ADV If
	       (S (NP-SBJ tests)
		  (VP indicated
		      (NP (NP a low number)
			  (PP of
			      (NP red cells))))))
     ,
     (NP-SBJ-1 blood)
     (VP was n't
         (VP taken
	     (NP *-1)))
     .))
( (S (NP-SBJ The EPO-treated patients)
     (VP donated
         (NP (NP an average)
             (PP of
                 (NP (NP 5.4 units)
		     (PP of
			 (NP blood))))
	     (NP-ADV each))
	 (PP compared
	     (PP with
		 (NP (NP (QP only 4.1) units)
		     (VP donated
			 (NP *)
			 (PP by
			     (NP-LGS (NP a similar group)
				     (PP of
					 (NP (NP surgical patients)
					     (SBAR (WHNP-1 who)
						   (S (NP-SBJ *T*-1)
						      (VP received
							  (NP a placebo injection)))))))))))))
     .))
( (S (S-TPC-1 (NP-SBJ (NP The volume)
		      (PP of
			  (NP (NP red cells)
			      (VP donated
				  (NP *)
				  (PP by
				      (NP-LGS the EPO-treated patients))))))
	      (VP was
		  (ADVP-PRD (NP 41 %) higher)
		  (PP per
		      (NP donor))))
     ,
     (NP-SBJ (NP the research team)
	     (VP representing
		 (NP (NP a number)
		     (PP of
			 (NP (NP hospitals)
			     and
			     (NP blood banks))))))
     (VP reported
	 (SBAR 0
	       (S *T*-1)))
     .))
